Prostate Cancer
Recent Abstracts
The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.
April 24, 2024
Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
April 23, 2024
Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition.
April 23, 2024
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression.
April 23, 2024
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers.
April 23, 2024
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways.
April 23, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the
April 23, 2024
Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies.
April 23, 2024
Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years.
April 23, 2024
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.
April 23, 2024
A Ten Year Experience of Men's Health Events in a Socioeconomically Diverse City in the United States - Lessons Learned.
April 23, 2024
Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency.
April 23, 2024
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
April 22, 2024
Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles.
April 22, 2024
Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer.
April 22, 2024
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
April 22, 2024
Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance.
April 22, 2024
Dietary Fiber Intake and Risk of Advanced and Aggressive Forms of Prostate Cancer: A Pooled Analysis of 15 Prospective Cohort Studies.
April 22, 2024
RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
April 22, 2024
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.
April 22, 2024
Page 31 of 1415
Start
Prev
26
27
28
29
30
31
32
33
34
35
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free